Visitors Now:
Total Visits:
Total Stories:
Profile image
By Global Market Insights Inc.
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Nimodipine Market 2016 Analysis and Forecasts to 2021 Research Report

Monday, October 17, 2016 3:30
% of readers think this story is Fact. Add your two cents.

(Before It's News) adds “Global Nimodipine Market Outlook 2016-2021” new report to its research database. The report spread across 101 pages with table and figures in it.

Nimodipine (marketed by Bayer as Nimotop) is a dihydropyridine calcium channel blocker originally developed for the treatment of high blood pressure. It is not frequently used for this indication, but has shown good results in preventing a major complication of subarachnoid hemorrhage (a form of cerebral hemorrhage) termed vasospasm.

Because it has some selectivity for cerebral vasculature, nimodipine’s main use is in the prevention of cerebral vasospasm and resultant ischemia, a complication of subarachnoid hemorrhage (a form of cerebral bleed), specifically from ruptured intracranial berry aneurysms irrespective of the patient’s post-ictus neurological condition. Its administration begins within 4 days of a subarachnoid hemorrhage and is continued for three weeks. If blood pressure drops by over 5%, dosage is adjusted. There is still controversy regarding the use of intravenous nimodipine on a routine basis.

Browse full table of contents and data tables at

A 2003 trial (Belfort et al.) found nimodipine was inferior to magnesium sulfate in preventing seizures in women with severe preeclampsia. Nimodipine is not regularly used to treat head injury. Several investigations have been performed evaluating its use for traumatic subarachnoid hemorrhage; a systematic review of 4 trials did not suggest any significant benefit to the patients that receive nimodipine therapy.

This report provides detailed analysis of worldwide markets for Nimodipine from 2011-2015 and provides extensive market forecasts 2016-2021 by region/country and subsectors. It covers the key technological and market trends in the Nimodipine market and further lays out an analysis of the factors influencing the supply/demand for Nimodipine, and the opportunities/challenges faced by industry participants. It also acts as an essential tool to companies active across the value chain and to the new entrants by enabling them to capitalize the opportunities and develop business strategies.

Request a sample copy at         

Global Nimodipine Market Outlook 2016-2021, has been prepared based on the synthesis, analysis, and interpretation of information about the global Nimodipine market collected from specialized sources. The report covers key technological developments in the recent times and profiles leading players in the market and analyzes their key strategies. The competitive landscape section of the report provides a clear insight into the market share analysis of key industry players. The major players in the global Nimodipine market are Bayer (Germany), Uquifa (Spain), Shandong Health (China), Ruikang Pharma (China), Kelun Group (China), Xinhua Pharmaceutical (China), Yabao Group (China), Central Pharm (China), among others.

The report provides separate comprehensive analytics for the North America, Europe, Asia-Pacific, Middle East and Africa and Rest of World. In this sector, global competitive landscape and supply/demand pattern of Nimodipine industry has been provided.

Enquiry before buying at    

To receive personalized assistance, write to us @ with the report title in the subject line along with your questions or call us at +1 866-764-2150

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.